Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096043 · ClinicalTrials.gov registry record · Phase 2
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT01096043: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01096043 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 69 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01096043, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study. The study is conducted in 3 different stages called 'strata" and evaluates the potential utility of this drug for the treatment of patents who are hospitalized with heart failure.
Primary Outcome
Define the safety and hemodynamic benefit of CXL-1020 based upon the change from baseline in hemodynamic measurements at the 6 hour time point in all strata
Interventions
- DRUG Placebo
- DRUG Strata 1 CXL-1020
- DRUG Strata 2 CXL-1020
- DRUG Strata 3 CXL-1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT01096043 record still lists
NCT01096043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01096043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01096043 about?
NCT01096043 is a clinical study titled "A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure". Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study. The study is conducted in 3 different stages called 'strata" and evaluates the potential utility of this drug for the treatment of patents who are hospita...
What is the current status of trial NCT01096043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2010-04. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01096043?
The interventions under investigation include: Placebo (DRUG), Strata 1 CXL-1020 (DRUG), Strata 2 CXL-1020 (DRUG), Strata 3 CXL-1020 (DRUG).
Who is sponsoring clinical trial NCT01096043?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01096043's enrollment target sits among peer trials
69 965th of 2000 higher than 1,034 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia